Yamo Pharmaceuticals, A Clinical Stage Pharmaceutical Company, Announced That The First Patient Has Been Treated In A Phase 2 Study Of L1-79 In Adolescents And Young Adults With Autism Spectrum Disorder (Asd) At Six Us Research Centers Of Excellence. L1-79 Is A Tyrosine Hydroxylase Inhibitor Designed To Improve The Socialization And Communication Symptoms By Modulating The Catecholaminergic Pathways Implicated In Asd.
